Herpes Simplex Virus Type 2 Prevalence and Association with Inflammatory Cytokines Among Sexual and Gender Minorities Living With and Without HIV-1 from Lagos,Nigeria
Restricted accessResearch articleFirst published online September, 2023
Herpes Simplex Virus Type 2 Prevalence and Association with Inflammatory Cytokines Among Sexual and Gender Minorities Living With and Without HIV-1 from Lagos,Nigeria
Herpes simplex virus type 2 (HSV-2) is common globally and contributes significantly to the risk of acquiring HIV-1, yet these two sexually transmitted infections have not been sufficiently characterized for sexual and gender minorities (SGM) across Sub-Saharan Africa. To help fill this gap, we performed a retrospective study using plasma and serum samples from 183 SGM enrolled at the Lagos site of the TRUST/RV368 cohort in Nigeria, assayed them for HSV-2 antibodies with the Kalon ELISA and plasma cytokines and chemokines with Luminex, and correlated the findings with HIV-1 viral loads (VLs) and CD4 counts. We found an overall HSV-2 prevalence of 36.6% (49.5% and 23.9% among SGM with and without HIV-1, respectively, p < .001). Moreover, HSV-2-positive status was associated with high circulating concentrations of CCL11 among antiretroviral therapy-treated (p = .031) and untreated (p = .015) participants, and with high concentrations of CCL2 in the untreated group (p = .004), independent of VL. Principal component analysis revealed a strong association of cytokines with HIV-1 VL independent of HSV-2 status. In conclusion, our study finds that HSV-2 prevalence among SGM with HIV-1 is twice as high than HSV-2 prevalence among SGM without HIV-1 in Lagos and suggests that this is associated with higher levels of certain systemic cytokines. Additional work is needed to further characterize the relationship between HSV-2 and HIV-1 in SGM and help develop targeted therapies for coinfected individuals.
Get full access to this article
View all access options for this article.
References
1.
LookerKJ, MagaretAS, TurnerKM, et al.Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One, 2015; 10(1):e114989; doi: 10.1371/journal.pone.0114989
2.
LookerKJ, ElmesJAR, GottliebSL, et al.Effect of HSV-2 infection on subsequent HIV acquisition: An updated systematic review and meta-analysis. Lancet Infect Dis, 2017; 17(12):1303–1316; doi: 10.1016/S1473-3099(17)30405-X
3.
LookerKJ, WeltonNJ, SabinKM, et al.Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: A population attributable fraction analysis using published epidemiological data. Lancet Infect Dis, 2020; 20(2):240–249; doi: 10.1016/S1473-3099(19)30470-0
4.
SchelarE, PolisC, EssamT, et al.Multipurpose prevention technologies for sexual and reproductive health: Mapping global needs for introduction of new preventive products. Contraception, 2016; 93(1):32–43.
5.
KouyoumjianSP, HeijnenM, ChaabnaK, et al.Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. AIDS, 2018; 32(10):1343–1352; doi: 10.1097/QAD.0000000000001828
BaetenJM, StrickLB, LucchettiA, et al.Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebo-controlled, cross-over trial. J Infect Dis, 2008; 198(12):1804–1808; doi: 10.1086/593214
8.
CrostarosaF, AravantinouM, AkpoghenetaOJ, et al.A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One, 2009; 4(11):e8060; doi: 10.1371/journal.pone.0008060
9.
GoodeD, TruongR, VillegasG, et al.HSV-2-driven increase in the expression of alpha4beta7 correlates with increased susceptibility to vaginal SHIV (SF162P3) infection. PLoS Pathogens, 2014; 10(12):e1004567; doi: 10.1371/journal.ppat.1004567
10.
Guerra-PerezN, AravantinouM, VegliaF, et al.Rectal HSV-2 infection may increase rectal SIV acquisition even in the context of SIVDeltanef Vaccination. PLoS One, 2016; 11(2):e0149491; doi: 10.1371/journal.pone.0149491
11.
MartinelliE, TharingerH, FrankI, et al.HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1cell target. PLoS Pathogens, 2011; 7(6):e1002109; doi: 10.1371/journal.ppat.1002109
12.
ZhuJ, HladikF, WoodwardA, et al.Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med, 2009; 15(8):886–892.
13.
MarsdenV, DonaghyH, BertramKM, et al.Herpes simplex virus type 2-infected dendritic cells produce TNF-alpha, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. J Immunol, 2015; 194(9):4438–4445; doi: 10.4049/jimmunol.1401706
14.
RollenhagenC, LathropMJ, MacuraSL, et al.Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: Implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides. Mucosal Immunol, 2014; 7(5):1165–1174; doi: 10.1038/mi.2014.3
15.
ShannonB, YiTJ, Thomas-PavanelJ, et al.Impact of asymptomatic herpes simplex virus type 2 infection on mucosal homing and immune cell subsets in the blood and female genital tract. J Immunol, 2014; 192(11):5074–5082; doi: 10.4049/jimmunol.1302916
16.
TobianAA, GrabowskiMK, SerwaddaD, et al.Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis, 2013; 208(5):839–846; doi: 10.1093/infdis/jit252
17.
FordES, MagaretAS, SpakCW, et al.Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. AIDS, 2018; 32(17):2525–2531; doi: 10.1097/QAD.0000000000002002
18.
FifeKH, MugwanyaK, ThomasKK, et al.Transient increase in herpes simplex virus type 2 (HSV-2)-associated genital ulcers following initiation of antiretroviral therapy in HIV/HSV-2-coinfected individuals. J Infect Dis, 2016; 213(10):1573–1578; doi: 10.1093/infdis/jiv765
19.
Mbopi KeouFX, GresenguetG, MayaudP, et al.Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS, 1999; 13(4):536–537; doi: 10.1097/00002030-199903110-00021
20.
Mbopi-KeouFX, LegoffJ, GresenguetG, et al.Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J Acquir Immune Defic Syndr, 2003; 33(2):121–124; doi: 10.1097/00126334-200306010-00001
21.
AuvertB, BallardR, CampbellC, et al.HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS, 2001; 15(7):885–898; doi: 10.1097/00002030-200105040-00009
22.
Mbopi-KeouFX, GresenguetG, MayaudP, et al.Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: Opportunities for intervention. J Infect Dis, 2000; 182(4):1090–1096.
23.
KapigaSH, SamNE, BangH, et al.The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis, 2007; 195(9):1260–1269.
24.
NagotN, OuedraogoA, KonateI, et al.Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis, 2008; 198(2):241–249; doi: 10.1086/589621
25.
SandlinMI, JohnstonC, BoweD, et al.Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. Sex Transm Dis, 2011; 38(9):833–836; doi: 10.1097/OLQ.0b013e31821a5d2c
26.
ZuckermanRA, LucchettiA, WhittingtonWL, et al.HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS, 2009; 23(4):479–483.
27.
CelumC, MorrowRA, DonnellD, et al.Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: A subgroup analysis of a randomized trial. Ann Intern Med, 2014; 161(1):11–19; doi: 10.7326/M13-2471
28.
MmbagaEJ, MoenK, LeynaGH, et al.HIV prevalence and associated risk factors among men who have sex with men in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr, 2018; 77(3):243–249; doi: 10.1097/QAI.0000000000001593
29.
KaulR, ProdgerJ, JoagV, et al.Inflammation and HIV transmission in sub-Saharan Africa. Curr HIV AIDS Rep, 2015; 12(2):216–222; doi: 10.1007/s11904-015-0269-5
30.
McKinnonLR, KarimQA. Factors driving the HIV Epidemic in Southern Africa. Curr HIV/AIDS Rep, 2016; 13(3):158–169; doi: 10.1007/s11904-016-0314-z
31.
van de WijgertJH, MorrisonCS, BrownJ, et al.Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Trans Dis, 2009; 36(6):357–364; doi: 10.1097/OLQ.0b013e3181a4f695
32.
MassonL, PassmoreJA, LiebenbergLJ, et al.Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis, 2015; 61(2):260–269; doi: 10.1093/cid/civ298
33.
ShannonB, GajerP, YiTJ, et al.Distinct effects of the cervicovaginal microbiota and herpes simplex type 2 infection on female genital tract immunology. J Infect Dis, 2017; 215(9):1366–1375; doi: 10.1093/infdis/jix088
34.
KahleEM, BoltonM, HughesJP, et al.Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: A nested case-control study among HIV-1-serodiscordant couples. J Infect Dis, 2015; 211(9):1451–1460; doi: 10.1093/infdis/jiu621
35.
NaranbhaiV, Abdool KarimSS, AltfeldM, et al.Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis, 2012; 206(7):993–1001; doi: 10.1093/infdis/jis465
36.
CoreyL, AdamsHG, BrownZA, et al.Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Annals of internal medicine, 1983; 98(6):958–972; doi: 10.7326/0003-4819-98-6-958
37.
PhippsW, SaracinoM, MagaretA, et al.Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis, 2011; 203(2):180–187; doi: 10.1093/infdis/jiq035
38.
BrownJM, WaldA, HubbardA, et al.Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS, 2007; 21(12):1515–1523; doi: 10.1097/QAD.0b013e3282004929
39.
ChaixML, CharreauI, PintadoC, et al.Effect of on-demand oral pre-exposure prophylaxis with tenofovir/emtricitabine on herpes simplex virus-1/2 incidence among men who have sex with men: A substudy of the ANRS IPERGAY trial. Open Forum Infect Dis, 2018; 5(11):ofy295; doi: 10.1093/ofid/ofy295
40.
ThienkruaW, ToddCS, ChonwattanaW, et al.Incidence of and temporal relationships between HIV, herpes simplex II virus, and syphilis among men who have sex with men in Bangkok, Thailand: An observational cohort. BMC Infect Dis, 2016; 16:340; doi: 10.1186/s12879-016-1667-z
41.
LiD, YangX, ZhangZ, et al.Incidence of co-infections of HIV, herpes simplex virus type 2 and syphilis in a large cohort of men who have sex with men in Beijing, China. PLoS One, 2016; 11(1):e0147422; doi: 10.1371/journal.pone.0147422
42.
XuF, SternbergMR, MarkowitzLE. Men who have sex with men in the United States: Demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: Results from National Health and Nutrition Examination Survey 2001–2006. Sex Trans Dis, 2010; 37(6):399–405; doi: 10.1097/OLQ.0b013e3181ce122b
43.
RemisRS, LiuJ, LoutfyMR, et al.Prevalence of sexually transmitted viral and bacterial infections in HIV-positive and HIV-negative men who have sex with men in Toronto. PLoS One, 2016; 11(7):e0158090; doi: 10.1371/journal.pone.0158090
44.
FerreVM, Gbeasor-KomlanviFA, CollinG, et al.Prevalence of human papillomavirus, human immunodeficiency virus, and other sexually transmitted infections among men who have sex with men in Togo: A national cross-sectional survey. Clin Infect Dis, 2019; 69(6):1019–1026; doi: 10.1093/cid/ciy1012
45.
UNAIDS. Country Progress Report—Nigeria. 2020. Available from: https://www.unaids.org/sites/default/files/country/documents/NGA_2020_countryreport.pdf [Last accessed: May20, 2022].
46.
StahlmanS, NowakRG, LiuH, et al.Online sex-seeking among men who have sex with men in Nigeria: Implications for online intervention. AIDS Behav, 2017; 21(11):3068–3077; doi: 10.1007/s10461-016-1437-3
47.
KeshinroB, CrowellTA, NowakRG, et al.High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. J Int AIDS Soc, 2016; 19(1):21270; doi: 10.7448/IAS.19.1.21270
48.
LeeVanE, HuF, MitchellAB, et al.Associations of gender identity with sexual behaviours, social stigma and sexually transmitted infections among adults who have sex with men in Abuja and Lagos, Nigeria. J Int AIDS Soc, 2022; 25(7):e25956; doi: 10.1002/jia2.25956
49.
CrowellTA, KeshinroB, BaralSD, et al.Stigma, access to healthcare, and HIV risks among men who sell sex to men in Nigeria. J Int AIDS Soc, 2017; 20(1):21489; doi: 10.7448/IAS.20.01.21489
50.
CharuratME, EmmanuelB, AkoloC, et al.Uptake of treatment as prevention for HIV and continuum of care among HIV-positive men who have sex with men in Nigeria. J Acquir Immune Defic Syndr, 2015; 68(Suppl. 2):S114–S123; doi: 10.1097/QAI.0000000000000439
51.
BaralSD, KetendeS, SchwartzS, et al.Evaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIV. J Acquir Immune Defic Syndr (1999), 2015; 68(Suppl. 2):S107–S113; doi: 10.1097/QAI.0000000000000438
52.
Delany-MoretlweS, JentschU, WeissH, et al.Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sex Transm Infect, 2010; 86(1):46–50; doi: 10.1136/sti.2009.036541
53.
LingappaJ, Nakku-JolobaE, MagaretA, et al.Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS, 2010; 21(9):611–616; doi: 10.1258/ijsa.2009.008477
54.
PatelEU, ManucciJ, KahleEM, et al.Erratum to: Precision of the Kalon Herpes simplex virus type 2 IgG ELISA: An international inter-laboratory assessment. BMC Infect Dis, 2017; 17(1):355; doi: 10.1186/s12879-017-2454-1
55.
ReisnerSL, BielloK, RosenbergerJG, et al.Using a two-step method to measure transgender identity in Latin America/the Caribbean, Portugal, and Spain. Arch Sex Behav, 2014; 43(8):1503–1514; doi: 10.1007/s10508-014-0314-2
56.
CherpesTL, MeynLA, HillierSL. Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay. J Clin Microbiol, 2003; 41(6):2758–2759; doi: 10.1128/JCM.41.6.2758-2759.2003
57.
MassonL, MlisanaK, LittleF, et al.Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: A cross-sectional study. Sex Transm Infect, 2014; 90(8):580–587; doi: 10.1136/sextrans-2014-051601
58.
Andersen-NissenE, ChangJT, ThomasKK, et al.Herpes simplex virus suppressive therapy in herpes simplex virus-2/human immunodeficiency virus-1 coinfected women is associated with reduced systemic CXCL10 but not genital cytokines. Sex Trans Dis, 2016; 43(12):761–764; doi: 10.1097/OLQ.0000000000000523
59.
RewardEE, MuoSO, OrabuezeINA, et al.Seroprevalence of herpes simplex virus types 1 and 2 in Nigeria: A systematic review and meta-analyses. Pathog Glob Health, 2019; 113(5):229–237; doi: 10.1080/20477724.2019.1678938
60.
McKinnonLR, LiebenbergLJ, Yende-ZumaN, et al.Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat Med, 2018; 24(4):491–496; doi: 10.1038/nm.4506
61.
ProdgerJL, GrayRH, ShannonB, et al.Chemokine levels in the penile coronal sulcus correlate with HIV-1 acquisition and are reduced by male circumcision in Rakai, Uganda. PLoS Pathog, 2016; 12(11):e1006025; doi: 10.1371/journal.ppat.1006025
62.
BlairCS, LakeJE, PassaroRC, et al.Brief Report: HIV-1 seroconversion is not associated with prolonged rectal mucosal inflammation. J Acquir Immune Defic Syndr, 2021; 86(5):e134–e138; doi: 10.1097/QAI.0000000000002601
63.
McInallyS, WallK, YuT, et al.Elevated levels of inflammatory plasma biomarkers are associated with risk of HIV infection. Retrovirology, 2021; 18(1):8; doi: 10.1186/s12977-021-00552-6
64.
TanDH, RaboudJM, SzadkowskiL, et al.Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. AIDS Res Hum Retrov, 2015; 31(3):276–281; doi: 10.1089/AID.2014.0183
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
